Anl.O

The company exhibits a distressed capital structure with negative total equity of -$8.3 million and total liabilities of $42.8 million exceeding total assets of $34.4 million. Long-term debt stands at $26.4 million, while cash and equivalents are limited to $8.1 million, resulting in a negative net cash position. The current ratio is 0.65, indicating potential short-term liquidity constraints, and the debt-to-equity ratio is -3.17, reflecting the negative equity base.

Profitability metrics are severely negative, with an operating income of -$35.7 million and net income of -$35.5 million against revenue of $5.0 million. Return on assets is -1.03, and return on equity is reported as 4.27, a mathematical artifact of the negative equity denominator rather than a sign of positive performance. The company generates negative operating cash flow of -$33.5 million and negative free cash flow of -$34.3 million, highlighting a heavy cash burn rate.

Revenue concentration data is not explicitly detailed in segments or geography, but total revenue is minimal at $5.0 million, suggesting early-stage commercialization or pre-revenue status typical of clinical-stage biotechnology firms. The lack of segment breakdown implies that revenue is likely derived from a single primary activity or licensing arrangement.

Growth trajectory cannot be assessed due to the absence of historical period data in the input. The current financial snapshot shows a significant mismatch between the market capitalization of $1.02 billion and the minimal revenue base, resulting in an EV/Revenue multiple of 207.82. This valuation implies that the market is pricing in significant future potential rather than current financial performance.

Risk assessment indicates medium liquidity risk and low dilution risk, with a key flag noting that net cash is negative after subtracting total debt. The negative equity position and high debt load relative to assets present substantial financial risk, requiring careful monitoring of cash runway and potential refinancing needs.

Recent observations include analyst estimates with a mean price target of $28.60 and a median of $23.00, suggesting a bullish outlook from coverage analysts. The mean recommendation is 1.67, with 2 strong buys and 4 buys, indicating strong analyst support despite the current financial losses. No specific news events or filing observations are detailed beyond the reconciler enqueue logs.

Revenue $5.0M; Operating income +32,5% YoY.

• ▍Revenue $5.0M
• ▍Operating income +32,5% YoY
• ▍Net income +31,5% YoY
• ▍Free cash flow +31,6% YoY
• ▍Net margin -710.6%

Revenue $0.00; Operating income +27,1% YoY.

• ▍Revenue $0.00
• ▍Operating income +27,1% YoY
• ▍Net income +52,5% YoY
• ▍Free cash flow +53,2% YoY

Revenue $0.00; Operating income −7,8% YoY.

• ▍Revenue $0.00
• ▍Operating income −7,8% YoY
• ▍Net income −85,8% YoY
• ▍Free cash flow −81,9% YoY